Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens
- 31 December 2005
- journal article
- research article
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 53 (4) , 307-310
- https://doi.org/10.1016/j.diagmicrobio.2005.03.004
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centresClinical Microbiology & Infection, 2005
- Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive PathogensClinical Infectious Diseases, 2005
- Antimicrobial Resistance to LinezolidClinical Infectious Diseases, 2004
- Tolerability, Pharmacokinetics, and Serum Bactericidal Activity of Intravenous Dalbavancin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004
- Activities of Dalbavancin In Vitro and in a Rabbit Model of Experimental Endocarditis Due to Staphylococcus aureus with or without Reduced Susceptibility to Vancomycin and TeicoplaninAntimicrobial Agents and Chemotherapy, 2004
- Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptideInternational Journal of Antimicrobial Agents, 2004
- Initial Quality Control Evaluations for Susceptibility Testing of Dalbavancin (BI397), an Investigational Glycopeptide with Potent Gram-Positive ActivityJournal of Clinical Microbiology, 2003
- Infection with Vancomycin-ResistantStaphylococcus aureusContaining thevanAResistance GeneNew England Journal of Medicine, 2003
- In VitroEvaluation of BI 397, a Novel Glycopeptide Antimicrobial AgentJournal of Chemotherapy, 2001
- In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibioticJournal of Antimicrobial Chemotherapy, 1999